Abstract

Absci Corporation. will report quarterly results on November 12, 2026 Pre-MKt; this preview summarizes last quarter’s performance, consensus forecasts for revenue, profitability, and EPS, and highlights the investment debate around its partnership-driven revenue pipeline.

Market Forecast

Market models for the current quarter point to revenue of 0.73 million US dollars, a year-over-year decline of 55.76%, with estimated EPS of -0.20 and EBIT of -33.55 million US dollars; the year-over-year EPS change implied by models is an improvement of 4.84%. Margin visibility remains limited; Street models embed continued operating losses and do not provide a consolidated gross margin or net margin forecast. The main business is expected to remain driven by partner-based programs; the near-term outlook emphasizes milestone timing and collaboration progress. The most promising segment remains partnerships, which is projected to contribute the bulk of revenue this quarter at an estimated 0.73 million US dollars, though declining year over year by 55.76%.

Last Quarter Review

Last quarter, Absci Corporation. reported revenue of 0.32 million US dollars, GAAP net loss attributable to shareholders of 33.21 million US dollars, and management did not disclose gross margin or net margin; adjusted EPS came in at -0.21 with a year-over-year change of 12.50%. The company’s core revenue came from partnerships totaling 0.32 million US dollars, reflecting year-over-year decline of 46.37%, as the cadence of milestones remained lumpy. Quarter-on-quarter, the net loss widened by 12.20% as operating costs continued to weigh while revenue recognition remained limited.

Current Quarter Outlook

Main business: partnership-derived revenue and milestones

Street expectations indicate that Absci Corporation.’s revenue will again come predominantly from partner engagements linked to discovery, research, and milestone activities. Given the estimate of 0.73 million US dollars, the key driver is the recognition of research services and any triggered collaboration milestones. The year-over-year decline in the model underscores the inherently uneven nature of milestone timing. In this setup, even a single milestone event can shift quarterly results, so timing updates during the call will be crucial for understanding the run-rate into the next quarter. Investors will focus on the backlog and the conversion of signed programs into revenue, as well as any commentary on new or expanded collaborations that could accelerate top-line momentum.

Most promising business: scaling collaborations under larger pharma frameworks

While consensus anticipates a small revenue base this quarter, the potential upside hinges on expanding the number and scope of collaborations with larger biopharma partners. If Absci Corporation. advances programs into later research stages or secures additional upfronts, milestone opportunities could re-accelerate revenue beyond the modeled 0.73 million US dollars. The company’s ability to broaden program count and increase milestone density is central to medium-term inflection. A key swing factor is whether partner pipelines progress to preclinical candidate selection, which can unlock higher-value milestones and set the stage for downstream economics in later years.

Stock-price drivers this quarter: revenue cadence, cash burn, and operating runway

The projected EBIT loss of approximately 33.55 million US dollars signals another heavy operating period. Investors will parse operating expense discipline, cash burn trajectory, and any commentary on liquidity runway and funding flexibility. A better-than-expected revenue print due to milestone recognition would modestly cushion losses, but the larger determinant for sentiment is evidence of pipeline advancement that improves visibility into future non-dilutive cash inflows. Any update on cost control initiatives or partnership structures that offset internal R&D spend would likely influence near-term valuation.

Analyst Opinions

Based on recent commentary tracked across financial media and street notes during the last six months, the prevailing tone is cautious, with a majority leaning bearish relative to near-term revenue expectations. The core rationale centers on the volatility of milestone timing, small absolute revenue base, and continued operating losses embedded in current-quarter models. Notably, several analysts emphasize that execution on partnership expansion is necessary before estimates can reset higher, and that quarterly volatility is likely to persist until a more consistent milestone cadence is established. The bearish view argues that while the technology roadmap might support long-term optionality, the next print is unlikely to provide enough top-line scale to shift the profitability trajectory meaningfully in the near term.